Literature DB >> 21979480

Severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy.

David C Lung1, Y H Chan, L Kwong, T L Que.   

Abstract

Mycoplasma pneumoniae is the commonest agent causing atypical pneumonia in children. Macrolides have long been used in the treatment of community-acquired pneumonia not responsive to beta-lactams alone. In this report, we describe the first locally acquired paediatric patient with severe community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae, possessing an A-to-G transition at position 2063 of the 23s rRNA gene. In addition, we have detected two more strains of macrolide-resistant Mycoplasma pneumoniae out of a total of 10 cases with chest infection that were confirmed by polymerase chain reaction. Therefore macrolide-resistant Mycoplasma pneumoniae accounted for 33% (3 out of 10 patients) of the polymerase chain reaction-confirmed cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21979480

Source DB:  PubMed          Journal:  Hong Kong Med J        ISSN: 1024-2708            Impact factor:   2.227


  6 in total

1.  In vitro subminimum inhibitory concentrations of macrolide antibiotics induce macrolide resistance in Mycoplasma pneumoniae.

Authors:  G Ou; Y Liu; Y Tang; X You; Y Zeng; J Xiao; L Chen; M Yu; M Wang; C Zhu
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  Insight into potent TLR2 inhibitors for the treatment of disease caused by Mycoplasma pneumoniae based on machine learning approaches.

Authors:  Muhammad Ishfaq; Ziaur Rahman; Muhammad Aamir; Ihsan Ali; Yurong Guan; Zhihua Hu
Journal:  Mol Divers       Date:  2022-04-29       Impact factor: 2.943

3.  Comparison of pyrosequencing, Sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant mycoplasma pneumoniae quasispecies in respiratory specimens.

Authors:  Kwok-Hung Chan; Kelvin K W To; Betsy W K Chan; Clara P Y Li; Susan S Chiu; Kwok-Yung Yuen; Pak-Leung Ho
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

4.  Low Bacterial Co-infection Invalidates the Early Use of Non-anti-Mycoplasma pneumoniae Antibiotics in Pediatric Refractory Mycoplasma pneumoniae Pneumonia Patients.

Authors:  Jin-Rong Liu; Jie Lu; Fang Dong; Hui-Min Li; Hui Liu; Xiao-Lei Tang; Yong-Li Guo; Shun-Ying Zhao
Journal:  Front Pediatr       Date:  2018-10-26       Impact factor: 3.418

5.  Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs.

Authors:  Ren Sun; Liya Wang
Journal:  BMC Microbiol       Date:  2013-08-06       Impact factor: 3.605

6.  Typical or atypical pneumonia and severe acute respiratory symptoms in PICU.

Authors:  Kam Lun Hon; Agnes S Y Leung; Kam Lau Cheung; Antony C Fu; Winnie Chiu Wing Chu; Margaret Ip; Paul K S Chan
Journal:  Clin Respir J       Date:  2014-06-09       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.